These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 2898229

  • 1. Parkinsonism: candidate disorder for implanted pumps?
    Nutt JG.
    Ann N Y Acad Sci; 1988; 531():194-9. PubMed ID: 2898229
    [No Abstract] [Full Text] [Related]

  • 2. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG.
    Neurology; 2006 May 23; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract] [Full Text] [Related]

  • 3. Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case.
    Rajput A, Kishore A, Snow B, Bolton CF, Rajput AH.
    Mov Disord; 1997 May 23; 12(3):453-6. PubMed ID: 9159748
    [No Abstract] [Full Text] [Related]

  • 4. Parkinson's disease and its chemotherapy.
    Hornykiewicz O.
    Biochem Pharmacol; 1975 May 15; 24(10):1061-5. PubMed ID: 239718
    [No Abstract] [Full Text] [Related]

  • 5. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP, Rüther E.
    Nervenarzt; 1985 Feb 15; 56(2):69-81. PubMed ID: 3982566
    [No Abstract] [Full Text] [Related]

  • 6. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Deleu D, Hanssens Y.
    Neurology; 2006 May 23; 66(10):1611-2; author reply 1611-2. PubMed ID: 16721952
    [No Abstract] [Full Text] [Related]

  • 7. Intravenous levodopa in hallucinating PD patients.
    Friedman JH.
    Neurology; 1999 Jan 01; 52(1):219-20. PubMed ID: 9921891
    [No Abstract] [Full Text] [Related]

  • 8. Are there clinically significant differences between dopamine agonists.
    Stocchi F, Vacca L, Onofrj M.
    Adv Neurol; 2003 Jan 01; 91():259-66. PubMed ID: 12442684
    [No Abstract] [Full Text] [Related]

  • 9. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
    Westin J, Nyholm D, Pålhagen S, Willows T, Groth T, Dougherty M, Karlsson MO.
    Clin Neuropharmacol; 2011 Jan 01; 34(2):61-5. PubMed ID: 21297456
    [Abstract] [Full Text] [Related]

  • 10. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D, Jansson R, Willows T, Remahl IN.
    Neurology; 2005 Nov 08; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract] [Full Text] [Related]

  • 11. Dopamine receptors in Parkinson's disease.
    Hassan MN, Thakar JH.
    Prog Neuropsychopharmacol Biol Psychiatry; 1988 Nov 08; 12(2-3):173-82. PubMed ID: 3290993
    [Abstract] [Full Text] [Related]

  • 12. Knotting of Duodopa® duodenal infusion system.
    del-Hoyo-Francisco J, Bustamante-Balén M, Martínez-Torres I, Barrios-Barrios A, Satorres-Paniagua C, Pons-Beltrán V.
    Rev Esp Enferm Dig; 2015 May 08; 107(5):323-4. PubMed ID: 25952811
    [No Abstract] [Full Text] [Related]

  • 13. Off-period screaming accompanying motor fluctuations in Parkinson's disease.
    Steiger MJ, Quinn NP, Toone B, Marsden CD.
    Mov Disord; 1991 May 08; 6(1):89-90. PubMed ID: 2005932
    [No Abstract] [Full Text] [Related]

  • 14. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ, Molina JA, Ortí-Pareja M.
    Rev Neurol; 1991 May 08; 28(9):889-98. PubMed ID: 10390756
    [Abstract] [Full Text] [Related]

  • 15. Levodopa therapy for Parkinson disease: A look backward and forward.
    LeWitt PA, Fahn S.
    Neurology; 2016 Apr 05; 86(14 Suppl 1):S3-12. PubMed ID: 27044648
    [Abstract] [Full Text] [Related]

  • 16. [Current views on the pathogenesis and pharmacotherapy of Parkinson disease].
    Kostowski W.
    Neurol Neurochir Pol; 1987 Apr 05; 21(6):541-7. PubMed ID: 2835696
    [No Abstract] [Full Text] [Related]

  • 17. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y, Graybiel AM, Ruberg M, Hirsch E, Blin J, Dubois B, Javoy-Agid F.
    Adv Neurol; 1990 Apr 05; 53():83-100. PubMed ID: 1978522
    [No Abstract] [Full Text] [Related]

  • 18. [New types of dopaminergic treatment. The Danish Society of Movement Disorders].
    Karlsborg M, Regeur L.
    Ugeskr Laeger; 2006 Mar 20; 168(12):1209. PubMed ID: 16571300
    [No Abstract] [Full Text] [Related]

  • 19. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L, Hellemans J.
    Tijdschr Gerontol Geriatr; 1982 Aug 20; 13(4):147-54. PubMed ID: 6127822
    [Abstract] [Full Text] [Related]

  • 20. L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.
    Russmann H, Ghika J, Combrement P, Villemure JG, Bogousslavsky J, Burkhard PR, Vingerhoets FJ.
    Neurology; 2004 Jul 13; 63(1):153-5. PubMed ID: 15249627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.